Archive ready
帝人株式会社の希少内分泌疾患ホルモン治療薬に関する契約締結のお知らせ
https://www.teijin.co.jp/news/2023/11/29/20231129_02.pdfMay 24, 2026 at 11:00 PM JST•The archive page, viewer, and downloads use this saved version.
May 24, 2026 at 11:00 PM JST·www.teijin.co.jp
The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
Saved PDF
帝人株式会社の希少内分泌疾患ホルモン治療薬に関する契約締結のお知らせ
StartedMay 24, 2026 at 11:00 PM JST
File size0.28 MB
SHA-2561953d02ffc491591bcb6108e12052703cc8b39c39294586ad878d126f1f16393
About this pageAI generated
This document announces that Teijin Limited has signed an exclusive licensing agreement with Ascendis Pharma, A/S for three hormone therapies targeting rare endocrine disorders. The drugs involved are 'TransCon hGH', 'TransCon PTH', and 'TransCon CNP', and the agreement grants Teijin rights for research, development, manufacturing, and sales in Japan. Teijin will pay an upfront fee and milestone payments to Ascendis. The company aims to expedite the development of these therapies to deliver them to patients in Japan as soon as possible.